The company that oversees Medicare plan reimbursement for patients in 11 western states including Colorado this week stopped paying for the use of the Amgen Inc. drug Aranesp as a treatment for ...
Getting your Trinity Audio player ready... PHILADELPHIA- In the latest blow to Amgen Inc., at least one company that administers Medicare plans has decided to stop paying for the use of the drug ...
DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Aranesp" drug pipelines has been added to ResearchAndMarkets.com's offering. Aranesp (darbepoetin alfa; Amgen/Kyowa Hakko Kirin) is a recombinant human ...
The one bright spot in the study was that it didn't uncover any new safety issues with Aranesp. At this point, however, the anemia drug has been associated with a variety of serious side effects in ...
More bad news for Amgen and its beleaguered anemia drug franchise: A giant trial finds the company's Aranesp drug nearly doubles the risk of strokes in kidney disease patients. Aranesp sales have ...
A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are ...
BARCELONA, Spain -- Sept. 26, 2007--Amgen today announced data from a Phase 2, randomized, multicenter, open-label study that suggest extended dosing of Aranesp(R) (darbepoetin alfa) paired with ...
Amgen Inc., the world’s largest biotechnology company, said Monday that U.S. regulators approved its Aranesp drug to treat anemia in cancer patients undergoing chemotherapy, creating competition for ...
Biotechnology giant Amgen today pleaded guilty in federal court to a misdemeanor charge of misbranding Aranesp (darbepoetin alfa), its highly successful anemia drug. The government accused Amgen of ...
LOS ANGELES (Reuters) - Amgen Inc. said on Monday that 48.5 percent of cancer patients not undergoing chemotherapy or radiation who received its anemia drug Aranesp in a clinical trial died compared ...
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen, Inc. (NASDAQ: AMGN - News) today announced that it had received interim results from the independent investigator-sponsored “PREPARE†study, an ...
NEW YORK, April 19 (Reuters) - Amgen Inc.'s. anemia drug Aranesp showed no increased risk of death compared to a placebo in a study of small-cell lung cancer patients undergoing chemotherapy, sending ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback